Quoted Portfolio Companies

CeNeS

York Pharma plc

Intercytex Ltd

Unquoted Portfolio Companies

Amura Ltd

Aitua Ltd

CellCentric Ltd

De Novo Pharmaceuticals

ImmunoBiology Ltd

Medical Device Innovation

Proteom

Purely Proteins

Sold Companies

Paradigm Therapeutics

Cozart plc

Sterix Limited

Cambridge Biotechnology L

Sangamo BioSciences

Saturday, May 10, 2008

Purely Proteins (PP) now operates as a virtual company seeking interesting opportunities in the UK life sciences sector. For further information please contact dan.roach@avlar.com.

TargetBase is now commercialised by ChiBio Informatics Limited. For more information please contact Dr David Parry-Smith on info@chibio.com. Further information is available at www.chibio.com

Portfolio News

18 April 2008
Intercytex plc: funding award from US Government

10 April 2008
Recommended Acquisition of CENES PHARMACEUTICALS PLC by PAION AG

10 April 2008
CeNeS Pharmaceuticals plc proposed acquisition by PAION AG

All Portfolio News

News Archive
2004 News Archive

Weather in Cambridge

Temp: N/A ºF

Last Updated: N/A

Our Investors

3i

Access Capital Partners

Astellas Venture Capital

Avlar management

BTG

Cambridge University

Coller Capital

European Investment Fund

Lloyds TSB DC

Lexington Partners Inc

Preferred Advisors

Morrison & Foerster MNP

Opportunities

CEOs with relevant experience for start-up / early stage Life Science companies.

Privacy Statement | Sitemap | © 2008 Avlar BioVentures Limited

Avlar BioVentures Limited is authorised and regulated by the Financial Services Authority, who require us to state that investments of this type are only suitable for experienced investors familiar with venture capital and biotechnology companies.